TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataIC50: 600nMAssay Description:Antagonist activity at TRPM5 (unknown origin)More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataIC50: 600nMAssay Description:Antagonist activity at TRPM5 (unknown origin)More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.70E+4nMAssay Description:Agonist activity at human TRPM5 in HEK293T cells by FLIPR based assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 7.90nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 631nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 794nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.58E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 50nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 501nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 316nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.26E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.00E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.00E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 7.94E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.00E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 6.31E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.59E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 4(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <1.58E+4nMAssay Description:Agonist activity at human TRPV4More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 316nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.00E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 100nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 200nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 200nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 63nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.00E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 3.16E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 126nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 7.94E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 251nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 125nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.00E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.45E+4nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.63E+4nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.82E+3nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.70E+3nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.57E+4nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.35E+3nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 8.91E+3nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 589nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.15E+4nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 4(Homo sapiens)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.14E+4nMAssay Description:Agonist activity at human TRPM4 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit by measuring membrane potential by FLIPR...More data for this Ligand-Target Pair